Editorials and Perspectives haematologica| 2013; 98 (8) 1169 four years. These results
were confirmed in the multicenter STop IMatinib (STIM) study. 14 The initial analysis …

Elsewhere in this issue of the journal Verma and colleagues [1] report a case in which a
complete molecular response (CMR) induced by imatinib treatment was sustained for at …

Abstract Abstract 859 Background Imatinib (IM) has greatly improved survival rates in
chronic myeloid leukemia*(* CML). However, all patients (pts) must continue treatment for an …

Residual disease in chronic myeloid leukemia patients may be assessed by various
molecular methods. After imatinib treatment a significant proportion of patients achieve …

Recent studies have demonstrated that some patients with chronic myeloid leukemia (CML)
can maintain remission after discontinuation of imatinib. A prerequisite is stable …

After 5 years of imatinib treatment 40–50% of chronic myeloid leukaemia (CML) patients will
have stable undetectable BCR-ABL by real-time quantitative RT-PCR (RQ-PCR) using strict …

Abstract Abstract 505 Background: Therapy with imatinib and other tyrosine kinase inhibitors
leads to complete cytogenetic response (CCyR) in 80-90% of patients in chronic phase (CP) …

The BCR-ABL tyrosine kinase inhibitor imatinib mesylate (Gleevec) induces complete
cytogenetic responses (CCR) in more than 85% of patients with chronic myelogenous …

This study examines the prognostic significance of early molecular response using an
expanded dataset in chronic myeloid leukemia patients enrolled in the International …

the response to interferon is unsatisfactory. Clearly, it would be desirable to be able to
identify up-front those patients unlikely to respond to non-transplant therapies such as …